Vossel K, Ranasinghe KG, Beagle AJ, et al. - Levetiracetam was well tolerated in this randomized clinical trial, and while it did not improve the primary outcome, it did improve performance on spatial memory and executive function tasks in patients with Alzheimer disease (AD) and epileptiform activity in a prespecified analysis.

• In total, 34 adults (21 women [61.8%]; mean [SD] age, 62.3 [7.7] years) with AD were recruited and randomized (17 candidates to group A and 17 candidates to group B).

• Thirteen candidates (38.2%) were categorized as having epileptiform activity.

• The trial was completed by 28 participants (82.4%), 10 of whom (35.7%) experienced epileptiform activity.

• Overall, levetiracetam therapy had no effect on NIH-EXAMINER composite scores or secondary measures.

• However, levetiracetam therapy enhanced performance on the Stroop interference naming subscale and the virtual route learning test in patients with epileptiform activity.

• There were no discontinuations of therapy due to adverse events.